Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Potential of BGB-43395 in Healthy Participants
NCT07820891Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of bgb-43395 in solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Area Under the Concentration Time Curve from Time Zero to Infinity up to 10 days, Area Under the Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration up to 10 days and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
bgb-43395
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07820891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820891.